资讯

Could endocrine therapy plus a CDK4/6 inhibitor offer a viable chemo-sparing option in hormone receptor (HR)-positive/HER2-positive breast cancer?
Our findings do not suggest high utilization of neoadjuvant chemotherapy is associated with a trade-off between perioperative and long-term outcomes,” the researchers wrote.
A recent meta-analysis reveals no link between pathologic complete response and long-term survival in rectal cancer, challenging its use as a surrogate endpoint.
Adding an immune checkpoint inhibitor to neoadjuvant chemotherapy can improve pathologic complete response rates and may improve survival in patients with muscle-invasive bladder cancer, research ...
ALNEO included patients with potentially resectable disease and treated them with neoadjuvant alectinib for two cycles, ...
In a Phase II trial, advanced ovarian patients with HRD alterations seemed to fare particularly well on Imunon's IMNN-001 plus standard chemo.
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...
I MUNON, Inc. (IMNN) said on Wednesday its first patient has been dosed with the firm’s lead candidate, IMNN-001, as part of ...
Initiation of additional trial sites and patient enrollment activities ongoing with multiple patients in screening LAWRENCEVILLE, N.J., July 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a ...
Natera has announced the initiation of the Phase II TEODOR trial of its Signatera test aimed at replacing chemotherapy with ...
Neoadjuvant immunochemotherapy and sequential transoral surgery, including TORS, appears to be a feasible strategy that yields favorable oncologic and functional outcomes for patients with resectable ...
ACCURATELY predicting which breast cancer patients will respond completely to neoadjuvant chemotherapy (NAC) remains a ...